CCN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Crit Care Nurse 1999 Sep; 19(4): 20-27

This Article
Right arrow Respond to This Article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheever, K.
Right arrow Articles by Genthner, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheever, K.
Right arrow Articles by Genthner, D
Critical Care Nurse, Vol 19, Issue 4, 20-27
Copyright © 1999 by American Association of Critical Care Nurses


Articles

Epoprostenol therapy for primary pulmonary hypertension

KH Cheever, B Kitzes, and D Genthner

Although a rare disease, PPH is deadly. Until recently, patients had little hope for remission of this disease. Originally viewed as a "bridge to transplantation," new research findings suggest that epoprostenol significantly improves PPH so that transplantation may not be necessary. Treatment with epoprostenol is difficult to manage, however, because it requires continuous central infusion. Nurses have a key role in ensuring that patients safely and effectively manage this therapy.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association of Critical-Care Nurses.